European Commission Publishes Expert Panel’s Recommendations on High Drug Prices
This month the European Commission published Innovative Payment Models for High-Cost Innovative Medicines, a report of the Expert Panel on effective ways of investing...
The Urgency of Compulsory Licensing Provision for Transfer of Technology in the Pandemic Treaty:...
Guest blog by Ronald Eberhard
The Intergovernmental Negotiating Body, established by the World Health Assembly, aims to draft a global pandemic prevention, preparedness, and response...
It is not too late to solve the know-how problem in the WHO Pandemic...
Introduction
One of the most important Intellectual Property (IP) problems which the Pandemic Accord negotiators need to solve is now in danger of being completely...
Cystic Fibrosis Buyers Club Shows the UK Government The Way
The move by a group of parents of children with cystic fibrosis (CF) to set up a buyers club to gain access to treatments...
Wrapping up 2022 with some noteworthy medicines, law and policy events
Welcome to our annual, highly biased, overview of noteworthy events in the field of medicines law and policy.
Also in 2022, Covid-19 remained a central...
Medicines price transparency: Ground still left to cover
Parts of this blog were previously published in the Lancet Regional Health Europe
Secret medicines prices are hotly debated as European health systems struggle to...
Wrapping up 2023 with some noteworthy medicines, law and policy developments
Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...
WHO Members meet to finalise the Pathogen Access and Benefit Sharing Instrument
In May 2025, the WHO member states adopted the Pandemic Agreement, but they left the work to establish an instrument for Pathogen Access and...
High medicines prices in Europe – do not Brexit the people
The issues of high priced medicines and problems with access to medicines have for many years been themes belonging to the realm of global...
The Waiver that Wasn’t: Is the pharma lobby responsible?
Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...